A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4165-4173

  Glynn, Sharon A ^a   Boersma, Brenda J ^a   Howe, Tiffany M ^a   Edvardsen, Hege ^b   Geisler, Stephanie B ^d,e   Goodman, Julie E ^f   Ridnour, Lisa A ^a   Lønning, Per E ^d,e   Børresen Dale, Anne Lise ^b   Naume, Bjorn ^b   Kristensen, Vessela N ^b,c   Chanock, Stephen J ^a   Wink, David A ^a   Ambs, Stefan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f GRADIENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; MITOMYCIN;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NORWAY; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MITOCHONDRIA; MULTIVARIATE ANALYSIS; NORWAY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SUPEROXIDE DISMUTASE; SURVIVAL RATE; UNITED STATES;

EID: 67449138836     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0119     Document Type: Article

References (50)

1. Cerutti PA. Prooxidant states and tumor promotion. Science 1985;227:375-381 (Pubitemid 15153495)
2. Forsberg L, de Faire U, Morgenstern R. Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys 2001;389:84-93. (Pubitemid 32911546)
3. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-285 (Pubitemid 37328863)
4. Bartsch H, NairJ. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer : role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006;391:499-510.
5. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001;3:323-327
6. Oberley LW, Buettner GR. Role of superoxide dismutase in cancer: a review. Cancer Res 1979;39:1141-1149 (Pubitemid 9183825)
7. St Clair DK, Wan XS, Oberley TD, Muse KE, St Clair WH. Suppression of radiation-induced neoplastic transformation by overexpression of mitochondrial superoxide dismutase. Mol Carcinog 1992;6:238-242 (Pubitemid 23022593)
8. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005;59:143-148 (Pubitemid 40603325)
9. Hur GC, Cho SJ, Kim CH, et al. Manganese superoxide dismutase expression correlates with chemosensitivity in human gastric cancer cell lines. Clin Cancer Res 2003;9:5768-5775 (Pubitemid 37499501)
10. Suresh A, Guedez L, Moreb J, Zucali J. Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 2003;120:457-463 (Pubitemid 36241502)
11. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996;226:561-565
12. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005;15:311-319 (Pubitemid 40676552)
13. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogen 2003;13:145-157 (Pubitemid 36324244)
14. Bastaki M, Huen K, Manzanillo P, et al. Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics 2006;16:279-286
15. Slanger TE, Chang-Claude J, Wang-Gohrke S. Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifiers, and risk of breast cancer in a German population. Cancer Causes Control 2006;17:1025-1031 (Pubitemid 44290767)
16. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:989-996 (Pubitemid 38756709)
17. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 1999;59:602-606 (Pubitemid 29076057)
18. Mitrunen K, Sillanpaa P, Kataja V, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001;22:827-829 (Pubitemid 32447933)
19. Cai Q, Shu XO, Wen W, et al. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 2004;6:R647-55.
20. Millikan RC, Player J, de Cotret AR, et al. Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and Whites. Breast Cancer Res 2004;6:R264-74.
21. Ambrosone CB, Ahn J, Singh KK, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005;65:1105-1111 (Pubitemid 40216474)
22. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008;111:93-101. (Pubitemid 352009233)
23. Lonning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007;18:1293-1306 (Pubitemid 47305001)
24. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-919 (Pubitemid 44018921)
25. Martin DN, Boersma BJ, Howe TM, et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 2006;6:257. (Pubitemid 44734183)
26. Geisler S, Lonning PE, AasT, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-2512 (Pubitemid 32685830)
27. Geisler S, Borresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-5588 (Pubitemid 37499478)
28. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-3478 (Pubitemid 46594079)
29. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997;181:140-145 (Pubitemid 27087276)
30. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32 Database issue:D528-32. (Pubitemid 38081714)
31. Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 1989;179:8-18. (Pubitemid 19149619)
32. Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 2002;94:2844-2854 (Pubitemid 34547682)
33. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502 (Pubitemid 43854964)
34. Polite BN, Cirrincione C, Fleming GF, et al. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840-Cancer and Leukemia Group B. J Clin Oncol 2008;26:2659-2665
35. Razmara A, Duckles SP, Krause DN, Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 2007;1176:71-81. (Pubitemid 47553127)
36. Hussain SP, Amstad P, He P, et al. p53-induced upregulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004;64:2350-2356 (Pubitemid 38523887)
37. Woodson K, Tangrea JA, Lehman TA, et al. Manganese superoxide dismutase (MnSOD) polymorphism, α-tocopherol supplementation and prostate cancer risk in the α-tocopherol, β-carotene cancer prevention study (Finland). Cancer Causes Control 2003;14:513-518
38. Kang D, Lee KM, Park SK, et al. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 2007;16:1581-1586 (Pubitemid 47294822)
39. Arsova-Sarafinovska Z, Matevska N, Petrovski D, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct 2008;26:771-777
40. Mikhak B, Hunter DJ, Spiegelman D, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels, and prostate cancer risk. Carcinogenesis 2008;29:2335-2340
41. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007;96:2181-2196 (Pubitemid 47477879)
42. Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 1994;40:8-15. (Pubitemid 23360156)
43. al Bekairi AM, Shah AH, Chaudhry MA, Qureshi S. Uric acid as an inhibitor of biochemical changes induced by cyclophosphamide in mice. Toxicol Lett 1991;58:69-75.
44. Sudharsan PT, Mythili Y, Selvakumar E, Varalakshmi P. Cardioprotective effect of pentacyclic triterpene, lupeol and its ester on cyclophosphamide- induced oxidative stress. Hum Exp Toxicol 2005;24:313-318 (Pubitemid 40942615)
45. Ueta E, Yoneda K, Kimura T, et al. Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and γ-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer 2001;94:545-550 (Pubitemid 32979547)
46. Ueta E, Yoneda K, Yamamoto T, Osaki T. Manganese superoxide dismutase negatively regulates the induction of apoptosis by 5-fluorouracil, peplomycin and γ-rays in squamous cell carcinoma cells. Jpn J Cancer Res 1999;90:555-564 (Pubitemid 29267710)
47. Chung YM, Park S, Park JK, KimY, Kang Y,Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000;159:95-101. (Pubitemid 30676219)
48. Wang M, Kirk JS, Venkataraman S, et al. Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1α and vascular endothelial growth factor. Oncogene 2005;24:8154-8166 (Pubitemid 41759814)
49. Kattan Z, Minig V, Leroy P, Dauca M, Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 2008;108:203-215 (Pubitemid 351311363)
50. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814 (Pubitemid 26225099)